Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
Status:
Completed
Trial end date:
2020-07-15
Target enrollment:
Participant gender:
Summary
This observational prospective single arm cohort study is designed to assess pain and bone
pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC)
patients receiving Radium-223 in a real life nuclear medicine practice setting. In addition,
overall survival, time to next tumor treatment (TTNT), time to first symptomatic skeletal
event (SSE), course of blood counts, and safety will be assessed.